Tumor necrosis factor blockade for treatment of inflammatory bowel disease: efficacy and safety. [electronic resource]
Producer: 20110301Description: 145-52 p. digitalISSN:- 1874-4702
- Adalimumab
- Anti-Inflammatory Agents -- adverse effects
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Certolizumab Pegol
- Clinical Trials as Topic
- Humans
- Immunoglobulin Fab Fragments -- therapeutic use
- Inflammatory Bowel Diseases -- drug therapy
- Infliximab
- Polyethylene Glycols -- therapeutic use
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.